BS_AD4JPN9Q
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 46.81340341655716
- age_years
- 1.816
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.357
- PANCREAS_BETA_CELLS+0.323
- HEDGEHOG_SIGNALING+0.307
- BILE_ACID_METABOLISM+0.270
- KRAS_SIGNALING_DN+0.263
- CHOLESTEROL_HOMEOSTASIS+0.259
- WNT_BETA_CATENIN_SIGNALING+0.252
- ADIPOGENESIS+0.238
- ESTROGEN_RESPONSE_EARLY+0.225
- ESTROGEN_RESPONSE_LATE+0.207
Top 10 suppressed
- MYC_TARGETS_V1-0.507
- ALLOGRAFT_REJECTION-0.492
- E2F_TARGETS-0.484
- IL6_JAK_STAT3_SIGNALING-0.441
- DNA_REPAIR-0.437
- UNFOLDED_PROTEIN_RESPONSE-0.420
- MYC_TARGETS_V2-0.408
- INTERFERON_GAMMA_RESPONSE-0.379
- G2M_CHECKPOINT-0.361
- INTERFERON_ALPHA_RESPONSE-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112300 | — | — | 0.869 |
| 2 | BS_273HKCT4 | DNET | — | 0.863 |
| 3 | BS_9RT63JD9 | low-grade glioma | — | 0.859 |
| 4 | SRR1418837 | GTEX | — | 0.858 |
| 5 | BS_KZPR01BD | DNET | — | 0.856 |
| 6 | BS_ZZPBANDD | DNET | — | 0.847 |
| 7 | aMVAC.P_003_TURBT_S220 | — | — | 0.842 |
| 8 | SRR1359123 | GTEX | — | 0.837 |
| 9 | SRR1485542 | GTEX | — | 0.835 |
| 10 | SRR5088840 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.357 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.323 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.307 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.263 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.259 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.252 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.238 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.225 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.207 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.175 | Inavolisib | — uncovered |
| PEROXISOME | 0.163 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.156 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.147 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.147 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.112 | Inavolisib | — uncovered |
| MYOGENESIS | 0.106 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.074 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.074 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.039 | Inavolisib | — uncovered |